

Nu00c3u00baria Eritja

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8201488/publications.pdf>

Version: 2024-02-01

33
papers

905
citations

430874

18
h-index

477307

29
g-index

33
all docs

33
docs citations

33
times ranked

1866
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>ARID1A</i> deficient cells require HDAC6 for progression of endometrial carcinoma. <i>Molecular Oncology</i> , 2022, 16, 2235-2259.	4.6	9
2	Autophagy in the physiological endometrium and cancer. <i>Autophagy</i> , 2021, 17, 1077-1095.	9.1	100
3	T-Type Calcium Channels as Potential Therapeutic Targets in Vemurafenib-Resistant BRAFV600E Melanoma. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1253-1265.	0.7	17
4	Small-Molecule Inhibitors (SMIs) as an Effective Therapeutic Strategy for Endometrial Cancer. <i>Cancers</i> , 2020, 12, 2751.	3.7	12
5	Targeted sequencing with a customized panel to assess histological typing in endometrial carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 585-598.	2.8	17
6	Therapeutic potential of the new TRIB3-mediated cell autophagy anticancer drug ABTL0812 in endometrial cancer. <i>Gynecologic Oncology</i> , 2019, 153, 425-435.	1.4	30
7	Tumor suppressive function of E2F4 on PTEN-induced serrated colorectal carcinogenesis. <i>Journal of Pathology</i> , 2019, 247, 72-85.	4.5	5
8	Tumor Heterogeneity in Endometrial Carcinoma: Practical Consequences. <i>Pathobiology</i> , 2018, 85, 35-40.	3.8	26
9	Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancer. <i>Autophagy</i> , 2017, 13, 608-624.	9.1	65
10	Endometrial Carcinoma: Specific Targeted Pathways. <i>Advances in Experimental Medicine and Biology</i> , 2017, 943, 149-207.	1.6	53
11	A Smad3-PTEN regulatory loop controls proliferation and apoptotic responses to TGF-β ² in mouse endometrium. <i>Cell Death and Differentiation</i> , 2017, 24, 1443-1458.	11.2	24
12	Palbociclib has antitumour effects on <i>Pten</i> deficient endometrial neoplasias. <i>Journal of Pathology</i> , 2017, 242, 152-164.	4.5	25
13	Tumour-microenvironmental blood flow determines a metabolomic signature identifying lysophospholipids and resolvin D as biomarkers in endometrial cancer patients. <i>Oncotarget</i> , 2017, 8, 109018-109026.	1.8	12
14	Deletion of <i>Pten</i> in CD45-expressing cells leads to development of T-cell lymphoblastic lymphoma but not myeloid malignancies. <i>Blood</i> , 2016, 127, 1907-1911.	1.4	7
15	Effects of the multikinase inhibitors Sorafenib and Regorafenib in PTEN deficient neoplasias. <i>European Journal of Cancer</i> , 2016, 63, 74-87.	2.8	13
16	Oral intake of genetically engineered high-carotenoid corn ameliorates hepatomegaly and hepatic steatosis in PTEN haploinsufficient mice. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016, 1862, 526-535.	3.8	6
17	Metabotyping human endometrioid endometrial adenocarcinoma reveals an implication of endocannabinoid metabolism. <i>Oncotarget</i> , 2016, 7, 52364-52374.	1.8	17
18	Modeling glands with PTEN deficient cells and microscopic methods for assessing PTEN loss: Endometrial cancer as a model. <i>Methods</i> , 2015, 77-78, 31-40.	3.8	12

#	ARTICLE	IF	CITATIONS
19	ETV5 transcription program links BDNF and promotion of EMT at invasive front of endometrial carcinomas. <i>Carcinogenesis</i> , 2014, 35, 2679-2686.	2.8	30
20	Combinatorial Therapy Using Dovitinib and ICI182.780 (Fulvestrant) Blocks Tumoral Activity of Endometrial Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 776-787.	4.1	12
21	Long-Term Estradiol Exposure Is a Direct Mitogen for Insulin/EGF-Primed Endometrial Cells and Drives PTEN Loss-Induced Hyperplastic Growth. <i>American Journal of Pathology</i> , 2013, 183, 277-287.	3.8	22
22	Combination of Vorinostat and caspase-8 inhibition exhibits high anti-tumoral activity on endometrial cancer cells. <i>Molecular Oncology</i> , 2013, 7, 763-775.	4.6	16
23	An inducible knock-out mouse to model cell-autonomous role of PTEN in initiating endometrial, prostate and thyroid neoplasias. <i>DMM Disease Models and Mechanisms</i> , 2013, 6, 710-20.	2.4	38
24	Three-dimensional epithelial cultures: a tool to model cancer development and progression. <i>Histology and Histopathology</i> , 2013, 28, 1245-56.	0.7	10
25	ER α -mediated repression of pro-inflammatory cytokine expression by glucocorticoids reveals a critical role for TNF α and IL1 β in lumen formation and maintenance.. <i>Journal of Cell Science</i> , 2012, 125, 1929-44.	2.0	11
26	KSR1 Is Overexpressed in Endometrial Carcinoma and Regulates Proliferation and TRAIL-Induced Apoptosis by Modulating FLIP Levels. <i>American Journal of Pathology</i> , 2011, 178, 1529-1543.	3.8	30
27	Nuclear factor- κ B2/p100 promotes endometrial carcinoma cell survival under hypoxia in a HIF-1 α independent manner. <i>Laboratory Investigation</i> , 2011, 91, 859-871.	3.7	33
28	A Novel Three-Dimensional Culture System of Polarized Epithelial Cells to Study Endometrial Carcinogenesis. <i>American Journal of Pathology</i> , 2010, 176, 2722-2731.	3.8	46
29	CK2 β Is Expressed in Endometrial Carcinoma and Has a Role in Apoptosis Resistance and Cell Proliferation. <i>American Journal of Pathology</i> , 2009, 174, 287-296.	3.8	42
30	Promoter hypermethylation and reduced expression of RASSF1A are frequent molecular alterations of endometrial carcinoma. <i>Modern Pathology</i> , 2008, 21, 691-699.	5.5	71
31	Nuclear factor- κ B activation is associated with somatic and germ line RET mutations in medullary thyroid carcinoma. <i>Human Pathology</i> , 2008, 39, 994-1001.	2.0	25
32	Loss of Heterozygosity in Endometrial Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2008, 27, 305-317.	1.4	18
33	Antioxidants block proteasome inhibitor function in endometrial carcinoma cells. <i>Anti-Cancer Drugs</i> , 2008, 19, 115-124.	1.4	51